The Oncology Institute Inc SEC Filings

The Oncology Institute, Inc. filed a current report stating that it issued a press release announcing its financial results for the three months ended September 30, 2025.

The company furnished the press release as Exhibit 99.1, which includes details about its results of operations and financial condition for the quarter, along with other financial information. The company notes that this information is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.

The Oncology Institute (TOI) reported a third‑party cybersecurity incident affecting an external software provider that is expected to cause a brief, immaterial delay in fee‑for‑service collections. The company said there is no indication from the provider that any patient personal information was compromised, and the investigation is ongoing.

TOI is working with the provider to mitigate impacts and restore normal billing operations. The disclosure was furnished under Regulation FD.

The Oncology Institute (TOI) reported a third‑party cybersecurity incident affecting an external software provider that is expected to cause a brief, immaterial delay in fee‑for‑service collections. The company said there is no indication from the provider that any patient personal information was compromised, and the investigation is ongoing.

TOI is working with the provider to mitigate impacts and restore normal billing operations. The disclosure was furnished under Regulation FD.

Amendment No. 4 to Schedule 13D discloses that M33 Growth I LP, M33 Growth I GP LLC and TOI M, LLC (the Reporting Persons) amended their prior Schedule 13D to report a registered block trade executed on September 4, 2025. In that transaction M33 sold 6,018,168 shares and TOI M sold 681,832 shares of Oncology Institute, Inc. common stock at $3.09 per share. After accounting for holdings and warrants, the Reporting Persons report beneficial ownership of 9,290,838 shares, representing 9.79% of the company’s outstanding common stock based on 93,504,767 shares outstanding as of August 5, 2025. M33 LP entered a 180-day lock-up with B. Riley beginning September 4, 2025, subject to early termination if the closing price exceeds 140% of the sale price for four of five trading days. Other prior disclosures remain unchanged.

Amendment No. 4 to Schedule 13D discloses that M33 Growth I LP, M33 Growth I GP LLC and TOI M, LLC (the Reporting Persons) amended their prior Schedule 13D to report a registered block trade executed on September 4, 2025. In that transaction M33 sold 6,018,168 shares and TOI M sold 681,832 shares of Oncology Institute, Inc. common stock at $3.09 per share. After accounting for holdings and warrants, the Reporting Persons report beneficial ownership of 9,290,838 shares, representing 9.79% of the company’s outstanding common stock based on 93,504,767 shares outstanding as of August 5, 2025. M33 LP entered a 180-day lock-up with B. Riley beginning September 4, 2025, subject to early termination if the closing price exceeds 140% of the sale price for four of five trading days. Other prior disclosures remain unchanged.

M33 Growth I L.P., M33 Growth I GP LLC and TOI M, LLC reported insider sales of common stock of Oncology Institute, Inc. (symbol shown as TOI/TOIIW) on 09/04/2025. The filing shows two sale transactions at $3.09 per share: 6,018,168 shares sold (reported with Code S) and 681,832 shares sold. After these transactions, the reporting persons are shown as beneficially owning 7,932,389 shares directly and 590,892 shares indirectly (the indirect shares are held by TOI M, LLC). The reporting entities are identified as a director and a 10% owner. The Form 4 is signed by Gabriel Ling in his capacity as managing member for the reporting entities.

Brad Hively, a director of Oncology Institute, Inc. (ticker shown as TOI), reported a sale of 20,221 shares of common stock on 08/19/2025 at a price of $4.06 per share. After the reported disposition he beneficially owned 622,980 shares in a direct capacity. The Form 4 was signed by an attorney-in-fact on 08/21/2025.

Oncology Institute, Inc. director Richard A. Barasch filed a Form 4 reporting his status as a director of the company. The provided data show no reported purchases, sales, acquisitions, or dispositions of Oncology Institute shares in this filing excerpt.

The Oncology Institute, Inc. has amended its prospectus supplement to add an at-the-market equity program allowing sales of up to $15,000,000 of its common stock through BTIG and B. Riley as sales agents. Sales may occur from time to time on Nasdaq or by block trades under mutually agreed placement notices; the company reported a last sale price of $4.11 per share on Nasdaq.

The Agents will receive up to 4.0% of gross proceeds as commissions, and the company agreed to reimburse agents for documented out-of-pocket expenses up to $75,000, with estimated offering expenses of approximately $300,000 (excluding agent compensation). Sales settle next trading day and there are no minimum sale requirements; the Agents are deemed underwriters and the company has agreed to indemnify them against certain liabilities.

The Oncology Institute reported higher revenue driven by dispensary growth but remained unprofitable and reduced debt while cash declined. Total operating revenue rose to $119.8 million for the quarter and $224.2 million for the six months ended June 30, 2025, up from $98.6 million and $193.2 million a year earlier, led by a sharp increase in dispensary sales to $62.6 million for the quarter. The company reduced long-term debt (net) to $75.0 million after a partial prepayment and raised gross proceeds of about $16.5 million in a private placement.

Despite revenue growth, TOI recorded operating losses and a net loss of $17.0 million for the quarter and $36.6 million for the six months. Cash and cash equivalents fell to $30.3 million from $49.7 million at year-end 2024, though management states it has sufficient liquidity for at least one year. Non-operating items included a $7.3 million increase in the fair value of conversion option derivative liabilities and elimination of marketable securities by June 30, 2025. The consolidated financials include significant consolidated VIE balances, including VIE liabilities of $284.1 million for which creditors lack recourse to TOI’s general credit.

The Oncology Institute, Inc. furnished a press release that discloses its financial results and additional financial information for the three months ended June 30, 2025. The filing states the press release is provided as Exhibit 99.1 and clarifies that the information is being furnished rather than filed under the Exchange Act, limiting certain legal liabilities. The report lists the company’s registered securities (common stock: TOI; redeemable warrants: TOIIW) on Nasdaq and identifies the company as an emerging growth company. No detailed financial tables or specific line-item results are included in the 8-K text itself; readers must refer to Exhibit 99.1 for the full figures.

The Oncology Institute, Inc. reported that director Richard Barasch resigned from the Board, effective August 12, 2025, and the company states his resignation was not due to any disagreement with the company on operations, policies or practices. Anne McGeorge will replace Mr. Barasch as Chair of the Board, signaling an immediate leadership transition at the board level. The company furnished a press release dated August 13, 2025 as Exhibit 99.1 under Regulation FD. The Form 8-K does not disclose financial statements, material transactions, or earnings information.